Table 2. First recurrence site and the first line treatment.
| All (n = 110) |
EGFRmt group (n = 51) |
EGFRwt group (n = 59) |
p value | ||
|---|---|---|---|---|---|
| Recurrence | 61 (55.5%) | 36 (70.6%) | 25 (42.4%) | 0.004 | |
| First recurrence site (overlapping) | Thoracic area | 54 | 30 | 24 | |
| Extrathoracic area | 35 | 21 | 14 | ||
| First line treatment | EGFR-TKI | 30 (49.2%) | 30 (83.3%, the first- and second-generation: n = 19, osimertinib: n = 11) | 0 (0%) | <0.001 |
| Systemic chemotherapy (cytotoxic chemotherapy and/or immunotherapy) | 12 (19.7%) | 0 (0%) | 12 (48.0%) | ||
| CRT (+ durvalumab) | 9 (14.8%) | 2 (5.6%) | 7 (28.0%) | ||
| Surgery | 3 (4.9%) | 0 (0%) | 3 (12.0%) | ||
| Radiotherapy | 4 (6.6%) | 3 (8.3%) | 1 (4.0%) | ||
| Observation | 1 (1.6%) | 0 (0%) | 1 (4.0%) | ||
| Unknown | 2 (3.3%) | 1 (2.8%) | 1 (4.0%) | ||
| Death | 32 (29.1%) | 20 (39.2%) | 12 (20.3%) | 0.036 | |
| Death cause | Lung cancer | 28 (87.5%) | 18 (90.0%) | 10 (83.3%) | 0.715 |
| Others | 3 (9.4%) | 2 (10.0%, arrythmia: n = 1, suffocation: n = 1) | 1 (8.3%, pancreatic cancer) | ||
| Unknown | 1 (3.1%) | 0 (0%) | 1 (8.3%) |
EGFR: epidermal growth factor receptor; EGFRmt: EGFR mutation; EGFRwt: EGFR wild-type; EGFR-TKI: EGFR-tyrosine kinase inhibitor; CRT: chemoradiotherapy